Show simple item record

dc.contributor.authorTaylor, Sallyen
dc.contributor.authorLaw, Kateen
dc.contributor.authorCoomber-Moore, Jakeen
dc.contributor.authorDavies, Michelleen
dc.contributor.authorThistlewaite, Fiona Cen
dc.contributor.authorCalvert, M.en
dc.contributor.authorAiyegbusi, O.en
dc.contributor.authorYorke, Janelleen
dc.date.accessioned2023-10-25T08:48:24Z
dc.date.available2023-10-25T08:48:24Z
dc.date.issued2023en
dc.identifier.citationTaylor S, Law K, Coomber-Moore J, Davies M, Thistlewaite F, Calvert M, et al. Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review. Systematic reviews. 2023 Sep 30;12(1):183. PubMed PMID: 37777816. Pubmed Central PMCID: PMC10541698. Epub 2023/10/01. eng.en
dc.identifier.pmid37777816en
dc.identifier.doi10.1186/s13643-023-02337-8en
dc.identifier.urihttp://hdl.handle.net/10541/626603
dc.description.abstractIntroduction: Adoptive cell therapy (ACT) is a rapidly evolving field. Patient-reported outcomes (PROs) allow patients to report the impact of treatment on their quality of life during and after treatment. The systematic review aims to characterise the breadth of PROs utilised in ACT cancer care and provide guidance for the use of PROs in this patient population in the future. Methods: A systematic search was conducted (MEDLINE, PsycINFO, Embase and CINAHL) in August 2021 by two reviewers. Search terms covered the following: "adoptive cell therapy", "patient-reported outcomes" and "cancer". Studies were included if they used a PRO measure to report the impact of ACT. The methodological quality of PROs was assessed. Forward and backward reference searching was conducted of any relevant papers. A quality grading scale was applied based on Cochrane and Revenson criteria for classification of high-quality studies. Key data from the studies and the included PROs was extracted by two researchers and tabulated. Results: One-hundred nine papers were identified; 11 papers were included. The majority of studies were single-arm trials or observational studies. Twenty-two different PROs were identified; none was ACT specific. The PROMIS-29 and EQ-5D were most commonly used. Few studies collected PRO data in the first 1-2 weeks. Four studies followed patients up for over a year, and a further four studies followed patients for approximately 3 months. Discussion: None of the PROs identified have been designed specifically for ACT. Appropriateness of existing instruments should be considered. It should be considered whether it is appropriate to collect data more frequently in the acute stage and then less frequently during follow-up. It should be considered if one tool is suitable at all time points or if the tool should be adapted depending on time since treatment. More research is needed to identify the exact timings of PRO assessments, and qualitative work with patients is needed to determine the most important issues for them throughout the treatment and follow-up.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1186/s13643-023-02337-8en
dc.titlePatient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic reviewen
dc.typeArticleen
dc.contributor.departmentChristie Patient Centred Research, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M204BX, UKen
dc.identifier.journalSystematic Reviewsen
dc.description.noteen]
refterms.dateFOA2023-10-25T09:32:17Z


Files in this item

Thumbnail
Name:
37777816.pdf
Size:
1.188Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record